Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

70
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
70
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.3K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.3K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.9K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.9K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

127
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
127
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

3.1K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
3.1K
Adrenergic Neurons: Neurotransmission01:27

Adrenergic Neurons: Neurotransmission

6.0K
Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which...
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Capsaicin Attenuates Arterial Calcification Through Promoting SIRT6-Mediated Deacetylation and Degradation of Hif1α (Hypoxic-Inducible Factor-1 Alpha).

Hypertension (Dallas, Tex. : 1979)·2022
Same author

A time-resolved ratiometric luminescent anthrax biomarker nanosensor based on an Ir(III) complex-doped coordination polymer network.

Journal of materials chemistry. B·2022
Same author

Survival to hospital discharge and neurological outcomes with targeted temperature management after in-hospital cardiac arrest: a systematic review and meta-analysis.

Annals of palliative medicine·2022
Same author

Comparing the efficacy of pharmacological and psychological treatment, alone and in combination, in children and adolescents with obsessive-compulsive disorder: A network meta-analysis.

Journal of psychiatric research·2022
Same author

Core self-evaluation as mediator between depressive symptoms and suicidal ideation in adolescents.

Journal of affective disorders·2022
Same author

An Extension of Testlet-Based Equating to the Polytomous Testlet Response Theory Model.

Frontiers in psychology·2022

Related Experiment Video

Updated: Apr 15, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.9K

Catecholamine pathway polymorphisms and antidepressant response.

Li Yin1, Xu Zhang2, Yi Huang1

  • 1Department of Psychiatry, West China Hospital of Sichuan University, Chengdu, Sichuan Province, China.

Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists
|April 10, 2015
PubMed
Summary
This summary is machine-generated.

Genetic variations in the dopamine receptor D4 (DRD4) gene are linked to how well Chinese patients with major depressive disorder respond to selective serotonin reuptake inhibitors (SSRIs). This finding may help personalize antidepressant treatment strategies.

Keywords:
antidepgenemajor depressive disorderselective serotonin reuptake inhibitorsingle nucleotide polymorphism

More Related Videos

A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites
13:35

A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites

Published on: March 1, 2018

15.5K
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.7K

Related Experiment Videos

Last Updated: Apr 15, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
07:56

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices

Published on: August 11, 2021

3.9K
A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites
13:35

A Convenient Method for Extraction and Analysis with High-Pressure Liquid Chromatography of Catecholamine Neurotransmitters and Their Metabolites

Published on: March 1, 2018

15.5K
Developing a Rat Model for Bipolar Disorder
04:42

Developing a Rat Model for Bipolar Disorder

Published on: May 2, 2025

1.7K

Area of Science:

  • Pharmacogenetics
  • Neuroscience
  • Genetics

Background:

  • Genes regulating catecholamine metabolism are key in antidepressant treatment response.
  • Investigating genetic polymorphisms in tyrosine and tryptophan pathways is crucial for understanding treatment efficacy.

Purpose of the Study:

  • To determine if genetic polymorphisms in tyrosine or tryptophan genes correlate with selective serotonin reuptake inhibitor (SSRI) treatment response in Chinese patients with major depressive disorder (MDD).

Main Methods:

  • 290 MDD patients received 6-week SSRI treatment in a randomized double-blinded study.
  • Comparison of allele, genotype, and haplotype frequencies between SSRI responders and non-responders in catecholamine genes.

Main Results:

  • The DRD4 gene rs1800544 polymorphism showed a significant difference between responders and non-responders (P=0.042).
  • The DRD4 rs1800544 CG genotype was more frequent in responders (51.4%) than non-responders (35.8%), with an 81.7% response rate.
  • No significant differences were found for polymorphisms in TPH, SLC6A2, SLC6A3, or DRD2 genes or for any gene haplotypes.

Conclusions:

  • Polymorphisms in the DRD4 gene are associated with SSRI treatment response in Chinese MDD patients.
  • This suggests DRD4 genotype may serve as a predictive biomarker for SSRI efficacy.